Hutchison China MediTech
Strategic partnership with Inmagene for drug candidate portfolio for immunological diseasesHutchison China MediTech
Initiation of rolling NDA submission for surufatinib in NETsHutchison China MediTech
Ground breaking ceremony for Shanghai manufacturing plantHutchison China MediTech
Surufatinib Phase III data in NETs at ESMO 2020 and Publication in The Lancet OncologyHutchison China MediTech
Initiation of global fruquintinib FRESCO-2 Phase III in mCRCHutchison China MediTech
Initiation of HMPL-453 China Phase II in advanced intrahepatic cholangiocarcinoma